{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:19:38Z","timestamp":1791062378646,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003574","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2003,10,20]],"date-time":"2003-10-20T00:00:00Z","timestamp":1066608000000}}],"reference-count":27,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003574.pub2","type":"journal-article","created":{"date-parts":[[2004,1,29]],"date-time":"2004-01-29T18:02:36Z","timestamp":1075399356000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease"],"prefix":"10.1002","volume":"2009","author":[{"given":"Anthony K","family":"Akobeng","sequence":"first","affiliation":[{"name":"Royal Manchester Children's Hospital; Oxford Road Manchester UK M13 9WL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Zachos","sequence":"additional","affiliation":[{"name":"The Hospital for Sick Children; Division of Gastroenterology, Hepatology & Nutrition; 555 University Avenue Toronto Ontario Canada M5G 1X8"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,10,20]]},"reference":[{"key":"10.1002\/14651858.CD003574.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1053\/gast.2001.24042","article-title":"An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial","volume":"120","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: A randomized double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(97)80083-9","article-title":"Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease","volume":"349","author":"Stack","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1572-0241.2003.07343.x","article-title":"Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease","volume":"98","author":"Baldassano","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","article-title":"Endoscopic and histologic healing with infliximab anti-tumor Necrosis factor antibodies in Crohn's Disease: a European multicentre trial","volume":"116","author":"D'Haens","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2036.2003.01414.x","article-title":"Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open label study","volume":"17","author":"Rutgeerts","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0016-5085(99)70224-6","article-title":"Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis","volume":"116","author":"Baert","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/gut.40.4.470","article-title":"Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease","volume":"40","author":"Bauditz","year":"1997","journal-title":"Gut"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1365-2036.2000.00777.x","article-title":"Review article: the clinical role of anti-TNF alpha antibody treatment in Crohn's disease","volume":"14","author":"Bell","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/0016-5085(94)90398-0","article-title":"Tumor necrosis factor -alpha producing cells in the intestinal musosa of children with inflammatory bowel disease","volume":"106","author":"Breese","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","article-title":"Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration","volume":"46","author":"Brown","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0016|cit16","unstructured":"Clarke M Oxman AD Cochrane Reviewers' Handbook 4.1.4 [updated October 2001]. In: The Cochrane Library, Issue 4, 2001. Oxford : Update software. Updated quarterly"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2249.1990.tb03334.x","article-title":"Tumour necrosis factor-alpha and interferon gamma production measured at the single cell level in normal and inflamed human intestine","volume":"81","author":"MacDonald","year":"1990","journal-title":"Clin Exp Immunol"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/gut.32.8.913","article-title":"Serum concentrations of tumour necrosis factor-alpha in childhood chronic inflammatory bowel disease","volume":"32","author":"Murch","year":"1991","journal-title":"Gut"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1053\/gast.2000.18160","article-title":"Tumor necrosis factor: Biology and therapeutic inhibitors","volume":"119","author":"Papadikas","year":"2000","journal-title":"Gastroenterolgy"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jama.281.12.1110","article-title":"Accuracy of data in abstracts of published research articles","volume":"281","author":"Pitkin","year":"1999","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1136\/bmj.319.7223.1480","article-title":"Management of Crohn's disease","volume":"319","author":"Rampton","year":"1999","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/gut.39.5.684","article-title":"Increased production of tumour necrosis factor-a, interleukin 1b, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease","volume":"39","author":"Reimund","year":"1996","journal-title":"Gut"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/cyto.1995.0029","article-title":"Chimeric anti TNF- alpha monoclonal antibody Ca2 binds recombinant trasmembrane TNF- alpha and activates immune effector functions","volume":"7","author":"Scallon","year":"1995","journal-title":"Cytokine"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/gast.2001.22122","article-title":"Inflammatory bowel disease: immunodiagnostics, immunotherapeutics and ecotherapeutics","volume":"120","author":"Shanahan","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003574.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/cyto.1995.1003","article-title":"The mouse\/human chimeric monoclonal antibody cA2 neutralizes in vitro and protects transgenic mice from cachexia and TNF- lethality in vivo","volume":"7","author":"Siegel","year":"1995","journal-title":"Cytokine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD003574.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T10:02:48Z","timestamp":1641204168000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003574.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2003,10,20]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2009,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003574.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10,20]]}}}